Mersana - About the company
Mersana is an acquired company based in Cambridge (United States), founded in 2001. It operates as a Developer of antibody-drug conjugates for the treatment of cancer. Mersana has raised $136M in funding from New Enterprise Associates and Wellington. The company has 3201 active competitors, including 1095 funded and 766 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma.
Company Details
Mersana Therapeutics develops antibody-drug conjugates for the treatment of cancer. The company is developing a biodegradable polymer platform known as Fleximer to create immunoconjugate therapies. Its antibody-drug conjugates deliver anti-tumor agents directly to cancerous cells. Its lead product XMT-1522 targets HER2 positive cancer cells.
- Website
- mersana.com
- Social
- Email ID
- *****@mersana.com
- Phone Number
- +1 **********
- Registered Address
- Cambridge, Massachusetts
Key Metrics
Founded Year
2001
Location
Cambridge, United States
Stage
Acquired
Total Funding
$136M in 9 rounds
Latest Funding Round
Investors
Ranked
90th among 3201 active competitors
Annual Revenue
$40.5M as on Dec 31, 2024
Employee Count
84 as on Feb 28, 2026
Similar Companies
Exit Details
Acquired by Day One (Nov 13, 2025)
Legal entities associated with Mersana
Mersana is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
MERSANA THERAPEUTICS, INC. CIN: 43562403 , United States, Active | Dec 26, 999 | $40.5M (As on Dec 31, 2024) | 104 (As on Dec 31, 2024) | - |
Mersana's acquisition details
Mersana got acquired by Day One on Nov 13, 2025 at an acquisition amount of $285M. It was facilitated by TD Securities, WilmerHale and Fenwick & West.
Click here to take a look at Mersana's acquisition in detail
Sign up to download Mersana's company profile
Mersana's funding and investors
Mersana has raised a total funding of $136M over 9 rounds. Its first funding round was on Aug 2008. Its latest funding round was a Series C round on Jun 16, 2016 for $*****. 5 investors participated in its latest round. Mersana has 15 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Mersana:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 16, 2016 | 6312396 | Series C | 5313333 | 8325984 | 8821499 | 6949784 |
Mar 01, 2016 | 8275842 | Series B | 2432466 | 7427915 | 7769701 | 4562291 |
Mar 03, 2015 | 4994847 | Series B | 6575261 | 8384659 |
Access funding benchmarks and valuations. Sign up today!View details of Mersana's funding rounds and investors
Mersana's founders and board of directors
Founder? Claim ProfileMersana's employee count trend
Mersana has 84 employees as of Feb 26. Here is Mersana's employee count trend over the years:
Uncover Mersana's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Mersana's Competitors and alternates
Top competitors of Mersana include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Mersana, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 75/100 | |
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 73/100 | |
7th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
8th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
9th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 72/100 | |
10th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
90th | Mersana 2001, Cambridge (United States), Acquired | Developer of antibody-drug conjugates for the treatment of cancer | $136M | 64/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Mersana's competitors? Click here to see the top ones
Mersana's Investments and acquisitions
Mersana has made no investments or acquisitions yet.
Reports related to Mersana
Here is the latest report on Mersana's sector:
News related to Mersana
Filter this listMedia has covered Mersana for a total of 13 events in the last 1 year, 5 of them have been about company updates.
•
Day One Completes Acquisition of Mersana TherapeuticsBakersfield•Jan 06, 2026•Day One, Mersana, Day One Journal
•
ZoomInfo Faces Investigation Initiated by Former Louisiana Attorney GeneralPR Newswire•Dec 06, 2025•ZoomInfo, Kahn Swick & Foti, Sprouts Farmers Market, CarMax and 1 other
•
Shareholder Alert: M&A Class Action Firm Investigates Mergers of TCBX, RNA, ATXS, and FSUNPR Newswire•Dec 02, 2025•Monteverde, Keystone Bancshares, Integrated Electrical Services, Anywhere Real Estate and 12 others
•
Ademi Firm Investigates Mersana Therapeutics Inc. Fair Price ConcernsPR Newswire•Nov 13, 2025•Ademi, Mersana
•
•
Mersana Therapeutics Provides Business Update and Announces Q2 2025 Financial ResultsGlobeNewswire•Aug 13, 2025•Mersana
•
Mersana Therapeutics Reports Positive Phase 1 Data for Emi-Le at ASCO 2025Benzinga•Jun 02, 2025•Mersana
•
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsGlobeNewswire•May 15, 2025•Mersana
•
•
Mersana Therapeutics Announces Upcoming Emi-Le Presentations at ASCO 2025GlobeNewswire•Apr 23, 2025•Mersana
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Mersana
Explore our recently published companies
- Specule - Delhi based, 2017 founded, Unfunded company
- Tech Hive Technologies - Rawalpindi based, 2017 founded, Unfunded company
- Wise Accelerate - Hanoi based, 2021 founded, Unfunded company
- AblyCon Global - Bengaluru based, 2014 founded, Unfunded company
- Civoya - 2025 founded, Unfunded company
- A Innovative Food Products - Ahmedabad based, 2016 founded, Unfunded company
